Showing 1921-1930 of 2105 results for "".
- Ublituximab Reduced Annualized Relapse Rate and Disability Progression in Multiple Sclerosishttps://practicalneurology.com/news/ublituximab-reduced-annualized-relapse-rate-and-disability-progression-in-multiple-sclerosis/2469621/In the phase 3 ULTIMATE trials (NCT03277261 and NCT03277248), ublituximab (UTX)(TG Therapeutics, New York, NY) decreased (ARR) and disability progression of relapsing multiple
- Nusinersen Treatment of Spinal Muscular Atrophy Provides Continued Motor Development and Studies Will Evaluate a Higher Dosehttps://practicalneurology.com/news/nusinersen-treatment-of-spinal-muscular-atrophy-provides-continued-motor-development-and-studies-will-evaluate-a-higher-dose/2469614/Continued development and studies of nusinersen (Spinraza; Biogen, Cambridge, MA), the first of several treatments for spinal muscular atrophy (SMA) developed in just the last 5 years, show sustained survival and improvement in motor function. Studies also suggest a higher dose may be more effect
- Diagnostic Kit Provides Accurate Spinal Muscular Atrophy Copy Number and Diagnosishttps://practicalneurology.com/news/diagnostic-kit-provides-accurate-spinal-muscular-atrophy-copy-number-and-diagnosis/2469589/A study published in The Journal of Molecular Diagnostics, showed an in vitro diagnostic kit (AmplideX Kit; Bio-Techne Corporation, Minneapolis, MN) has accuracy for timely results of carrier identification or diagnosis of spinal muscular atrophy (SMA). In the study, the single-tu
- Increased Risk of Dementia Correlates With Decreased Kidney Functionhttps://practicalneurology.com/news/increased-risk-of-dementia-correlates-with-decreased-kidney-function/2469588/In a registry-based study published in Neurology, individuals with reduced kidney function had increased risk of dementia development. In the study, there were cases of dementia per 1,000 person-years in individuals with a normal kidney filtration rate of 90 to 104 mL per minute and with severe k
- Soticlestat Reduces Seizure Frequency in Developmental and Epileptic Encephalopathieshttps://practicalneurology.com/news/soticlestat-reduces-seizure-frequency-in-developmental-and-epileptic-encephalopathies/2469584/Long-term treatment with soticlestat (OV935/TAK935; Ovid Therapeutics, New York, NY) in individuals with developmental and epileptic encephalopathies (DEE) reduced seizure frequency in the ENDYMION open-label extension study (
- SAGE Cognitive Screening Tool Increased Detection of Cognitive Declinehttps://practicalneurology.com/news/sage-cognitive-screening-tool-increased-detection-of-cognitive-decline/2469582/In a study presented at the American Academy of Neurology Virtual Annual Meeting April 17-22, use of a self-administered gerocognitive examination (SAGE) combined with an informant report of significant cognitive decline over a year increased detection of cognitive impairment 15-fold. SAGE is a w
- Vidofludimus Calcium a Selective T- and B-Cell Reduced Multiple Sclerosis Disease Activityhttps://practicalneurology.com/news/vidofludimus-calcium-a-selective-t-and-b-cell-reduced-multiple-sclerosis-disease-activity/2469566/In the phase 2 EMPhASIS trial (NCT03846219) vidofludimus calcium (VFC)(IMU-838; Immunic, New York, NY) reduced new combined unique active (CUA) MRI lesions in individuals with multiple sclerosis (MS). CUA is a measure that counts uniqu
- Ublituximab Treatment Lessened Disability for People With Multiple Sclerosishttps://practicalneurology.com/news/ublituximab-treatment-lessened-disability-for-people-with-multiple-sclerosis/2469565/Treatment of people with relapsing multiple sclerosis (MS) with ublituximab (UTX)(TG Therapeutics; New York, NY) slowed progression of MS as measured with biomarkers and disability progression. Compared with teriflunomide (TFM), ublituximab reduced annualized rate of relapse (ARR), gadolinium enh
- Another Phase 3 Trial of PB-TURSO for Amyotrophic Lateral Sclerosis Being Initiated at FDA Requesthttps://practicalneurology.com/news/another-phase-3-trial-of-pb-turso-for-amyotrophic-lateral-sclerosis-being-initiated-at-fda-request/2469554/A phase 3 trial of sodium phenylbutyrate-taurursodiol (PB-TURSO) (AMX0035; Amylyx Pharmaceuticals, Cambridge, MA) for amyotrophic lateral sclerosis (ALS) is expected to start in the 3rd quarter of 2021. In a nearly 3-year overall survival analysis, those treated with PB-TURSO had a 44% decr
- Stem-Cell Treatment Improves Multiple Sclerosis Disability in Phase 2 Trialhttps://practicalneurology.com/news/phase-2-study-evaluating-msc-ntf-as-a-treatment-for-progressive-ms/2469545/In a phase 2 trial (NCT03799718), 3 repeated administrations of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treat